EUDAMED Registration

by | Nov 2, 2020 | FDA, Medical Devices, Quality, Registration, Regulatory

The EUDAMED Actors module is all set to start accepting registrations from member states and economic operators from 1st December 2020.  EUDAMED is a portal that consists of 6 modules and the Actors module serves as the establishment registration portal in the EU.1

Any organization who performs the following roles must register in the actors module and obtain a Single Registration Number (SRN):1

  • Commissions
  • Competent authority (CA)
  • Designating Authority (DA)
  • Notified Bodies (NB)
  • Manufacturers (MF)
  • Authorized Representative (AR)
  • System and Procedure Pack Producer (PR)
  • Importer (IM)

Distributors do not have to be registered in the EUDAMED.1

After registration, the economic operators will be approved by a competent authority and will be granted an SRN. The SRN uniquely identifies every economic operator and a new SRN must be obtained for each role of the organization. E.g. an organization which is a manufacturer as well as an importer must obtain two SRNs for each of its operations.1

For non-EU manufacturers, their authorized representative must verify their registration request before it is submitted to the competent authority for approval. To process the registration, all registrants must submit a signed declaration of information security responsibilities, and non-EU manufacturers must also submit a mandate summary document and must have an active authorized representative.1 While operators are not required to register immediately, you must register in the actors module before you can access the device module which is set to release in May 2021.1

Need help with EU MDR? Call us today at +1 249-987-4497 or email us at to know more about how we can help.

1EU Commission (2020) Actor Roles and Actor Registration Process retrieved on 10/29/2020 from

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This